THERASSAY is a core facility of functional exploration in small animals which supplies to academic and industrial research groups a large range of technological equipment and scientific expertise.
This open core facility offers a unique service, from the generation of animal models to highly specialized functional analyses of cardiovascular, metabolic, respiratory, digestive and motor functions as well as tumorigenesis exploration. THERASSAY involves multi-disciplinary teams from Inserm UMR_S 1087, UMR_S 1235, UMR_S 1089, UMR_S 1232 (Nantes, France).
THERASSAY is integrated in Biogenouest (Western France life science and environment core facility network) and IBiSA (national core facility network) and receives support from the Pays de la Loire regional council.
THERASSAY accepts to perform projects as services or collaborations.
THERASSAY also offers an access to the equipment and the training to the technological know-how of the core facility for internal or external students, technicians and researchers.
FC obtained his PhD in 1991 and is currently research director at the French National Institute of Health and Medical Research. He leads the team 1 “Cardiac diseases and sudden death” of the research unit of the Institut du Thorax (Inserm UMR 1087 – CNRS UMR 6291) and the “cardiac” module of the Therassay core facility. FC has a strong expertise in cardiac electrophysiology. He is interested in the mechanisms of cardiac arrhythmias and conduction defects by an integrative approach from gene to in vitro and in vivo function. He is recognized for his work on Nav1.5 and progressive cardiac conduction disease. FC is the author or co-author of ~ 60 articles published in peer-reviewed journals. He was or still is a member of various national evaluation committees or scientific councils of foundations.
GL hold a PhD (1988) has a strong expertise in the molecular mechanisms and intracellular signalling regulating smooth muscle cell contractility and arterial tone. She is leading the team 2 “Signalling and hypertension” of Inserm Unit 1087 and of the “vascular” module of Therassay core facility. GL authored or co-authored ~90 articles in peer-reviewed journals. GL is recognized as a key player in the elucidation of the role of Rho proteins in the pathogenesis of vascular diseases and is invited on a regular basis to provide conferences in Europe and the USA. GL is member of scientific board of several national comities.
AM is Professor of Respiratory Medicine at “Faculté de Médecine de Nantes, Université de Nantes”, Nantes, France and is the head of the “Service de Pneumologie” within “L’institut du thorax”, Nantes, France. The clinical activity of the department is devoted to acute respiratory care, with a specific orientation on severe asthma and allergy, cystic fibrosis, pulmonary hypertension and lung transplantation.
In research, Pr Magnan’s main field of activity is “Bronchial diseases and allergies”. This includes the investigation of T cell activation in asthma and lung transplant recipients, both in humans and in murine models (Inserm UMR 1087 – CNRS UMR 6291). The team develops both clinical and basic research in a translational approach. Pr Magnan leads the COLT (COhort in Lung Transplantation) program among the 11 French lung transplantation centers as principal investigator. He has published about 100 peer-reviewed articles in English.
Cédric Le May
Doctor in science (2004), CLM is a researcher at the CNRS. He is a member of team 4 “Dyslipidemias & lipotoxicity” of the research unit of the Thorax Institute (Inserm UMR 1087 – CNRS UMR 6291) and manages the metabolism module of the Therassay core facility. CLM has a strong expertise in the field of carbohydrate and lipid metabolism, focusing on the search for new ways to reduce plasma cholesterolemia and associated cardiovascular risks. His recent work on the PCSK9 protein (Proprotein Convertase Subtilisin Kexin type 9) and on a new pathway of intestinal cholesterol elimination called “TICE” gave it international recognition CLM is the author or co-author of ~ 45 articles published in peer-reviewed journals.
CH obtained his PhD in 1993 and is currently researcher at the University of Nantes. He leads the “Muscle & Cognition” module of the Therassay core Facility. CH has a strong expertise in skeletal muscle physiology. He is interested in the mechanisms of skeletal muscle force and calcium homeostasis defects by an integrative approach from gene to in vitro and in vivo function. CH is the author or co-author of 33 articles published in peer-reviewed journals. In 2014, she and his collaborators characterize a new transgenic rat model of Duchenne muscular dystrophy.
MN is Inserm Research director and current director of the Neurogastroenterology Inserm UMR 913, one of the research unit of the Institut des Maladies de l’Appareil Digestif (IMAD). Since 2000, MN team developed a research program aimed at understanding the role of the enteric nervous system (ENS) in the regulation of intestinal barrier functions in health and diseases. In this context, his team participated in the development of new field in Neurogastroenterology, studying the neuronal and glial regulation of intestinal barrier function (permeability, wound healing, epithelial cell proliferation). In parallel, his group developed and used new diagnostic and interventional endoscopic based approaches to characterize IEB and ENS dysfunctions in digestive (IBD, IBS) as well as extra-digestive diseases (Parkinson’s disease). Finally, his team demonstrated the ability of neurostimulation or nutrients based approaches to induce neurosplastic/neuroprotective changes in the ENS leading to improved gastrointestinal functions.
EM obtained her PhD in Molecular and Cellular Biology from the University of Nantes in 2009 focusing on Multiple Myeloma and Mcl-1. Identifying an opportunity in the marketplace for human myeloma cell line testing services, EM went straight on from her doctorate to create Myelomax. After 8 years at the head of Myelomax, she leads the “Onco-Hematology” module of the Therassay core facility. EM brings her expertise in the development of preclinical services in the field of onco-hematology with the support of team 10 researchers of the CRCINA (Inserm UMR1232) and clinicians of the hematology department of the University Hospital of Nantes.